Display options
Cite
Harouki N, Nicol L, Remy-Jouet I, et al. The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure. JACC Basic Transl Sci. 2017;2(4):418-430doi: 10.1016/j.jacbts.2017.06.005.
Harouki, N., Nicol, L., Remy-Jouet, I., Henry, J. P., Dumesnil, A., Lejeune, A., Renet, S., Golding, F., Djerada, Z., Wecker, D., Bolduc, V., Bouly, M., Roussel, J., Richard, V., & Mulder, P. (2017). The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure. JACC. Basic to translational science, 2(4), 418-430. https://doi.org/10.1016/j.jacbts.2017.06.005
Harouki, Najah, et al. "The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure." JACC. Basic to translational science vol. 2,4 (2017): 418-430. doi: https://doi.org/10.1016/j.jacbts.2017.06.005
Harouki N, Nicol L, Remy-Jouet I, Henry JP, Dumesnil A, Lejeune A, Renet S, Golding F, Djerada Z, Wecker D, Bolduc V, Bouly M, Roussel J, Richard V, Mulder P. The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure. JACC Basic Transl Sci. 2017 Aug 28;2(4):418-430. doi: 10.1016/j.jacbts.2017.06.005. eCollection 2017 Aug. PMID: 30062160; PMCID: PMC6034492.
Copy Download .nbib Format: NLM
Share it on

JACC Basic Transl Sci. 2017 Aug 28;2(4):418-430. doi: 10.1016/j.jacbts.2017.06.005. eCollection 2017 Aug.

The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure.

JACC. Basic to translational science

Najah Harouki, Lionel Nicol, Isabelle Remy-Jouet, Jean-Paul Henry, Anais Dumesnil, Annie Lejeune, Sylvanie Renet, Francesca Golding, Zoubir Djerada, Didier Wecker, Virginie Bolduc, Muriel Bouly, Jerome Roussel, Vincent Richard, Paul Mulder

Affiliations

  1. INSERM U1096, Rouen, France.
  2. Normandy University, IRIB, Rouen, France.
  3. Unité de formation et de recherche de Médecine et Pharmacie, Rouen University, Rouen, France.
  4. Plateau d'Imagerie CardioThoracique de l'Université de Rouen, Rouen, France.
  5. Pharmacology Department, Centre Hospitalier Universitaire de Reims, Reims, France.
  6. Bruker Biospin MRI GMBH, Ettlingen, Germany.
  7. Institut de Recherches Internationales Servier, Suresnes, France.

PMID: 30062160 PMCID: PMC6034492 DOI: 10.1016/j.jacbts.2017.06.005

Abstract

This study reports preclinical data showing that the interleukin (IL)-1β modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction, administration of the IL-1β antibody gevokizumab improves 'surrogate' markers of survival (i.e., left ventricular remodeling, hemodynamics, and function as well as coronary function). However, whether IL-1β modulation per se or in combination with standard treatments of heart failure improves long-term outcome in human heart failure remains to be determined.

Keywords: GK, Goto-Kakisaki; I/R, ischemia/reperfusion; IL, interleukin; IL-1β; LV, left ventricle/ventricular; LVEDP, left ventricular end-diastolic pressure; LVEDPV, left ventricular end-diastolic pressure–volume relationship; LVESP, left ventricular end-systolic pressure; LVESPVR, left ventricular end-systolic pressure–volume relationship; ROS, reactive oxygen species; SOD, superoxide dismutase; cardiovascular function; heart failure; ischemia/reperfusion

References

  1. Arch Immunol Ther Exp (Warsz). 2009 May-Jun;57(3):165-76 - PubMed
  2. Eur J Heart Fail. 2003 Jun;5(3):229-39 - PubMed
  3. Am J Cardiol. 2015 Feb 1;115(3):288-92 - PubMed
  4. MAbs. 2011 Jan-Feb;3(1):49-60 - PubMed
  5. Curr Diab Rep. 2009 Feb;9(1):79-86 - PubMed
  6. Horm Metab Res. 2006 Sep;38(9):575-86 - PubMed
  7. Circulation. 2004 Apr 6;109(13):1594-602 - PubMed
  8. Diabetes. 2010 Apr;59(4):1063-73 - PubMed
  9. Am J Physiol Cell Physiol. 2001 Jan;280(1):C53-60 - PubMed
  10. JACC Heart Fail. 2014 Apr;2(2):131-7 - PubMed
  11. Circulation. 2010 Feb 2;121(4):519-28 - PubMed
  12. Circulation. 2013 Oct 22;128(17):1910-23 - PubMed
  13. Circulation. 2008 Aug 19;118(8):818-27 - PubMed
  14. J Am Coll Cardiol. 2016 May 3;67(17):2050-60 - PubMed
  15. Mol Cell Biochem. 2008 Oct;317(1-2):43-50 - PubMed
  16. Circulation. 2004 Apr 6;109(13):1674-9 - PubMed
  17. J Intern Med. 2012 Sep;272(3):267-76 - PubMed
  18. Circulation. 1997 Sep 16;96(6):1976-82 - PubMed
  19. Nature. 1996 Nov 28;384(6607):353-5 - PubMed
  20. Biochem Biophys Res Commun. 1990 Jan 15;166(1):324-9 - PubMed
  21. J Biol Chem. 2010 Jul 2;285(27):20607-14 - PubMed
  22. Eur J Heart Fail. 2010 Apr;12(4):319-22 - PubMed
  23. Circulation. 2016 Apr 12;133(15):1484-97; discussion 1497 - PubMed
  24. Am J Physiol. 1995 Aug;269(2 Pt 2):R229-35 - PubMed
  25. Circulation. 2008 Jan 1;117(1):43-51 - PubMed
  26. J Cardiovasc Pharmacol. 2010 Feb;55(2):117-22 - PubMed
  27. Circulation. 1985 Aug;72(2):406-12 - PubMed
  28. Kidney Int. 1990 Feb;37(2):767-75 - PubMed
  29. J Pediatr Endocrinol Metab. 2003 Feb;16(2):203-10 - PubMed
  30. J Am Coll Cardiol. 2001 Nov 1;38(5):1546-53 - PubMed
  31. Clin Immunol. 2015 Oct;160(2):155-62 - PubMed
  32. Circ Res. 2003 Jul 25;93(2):e9-16 - PubMed
  33. Cell Calcium. 2010 Apr;47(4):378-86 - PubMed
  34. Eur Heart J. 2008 Sep;29(17):2171-9 - PubMed
  35. Nat Rev Cardiol. 2012 Dec;9(12):717-33 - PubMed
  36. Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H153-62 - PubMed
  37. Circulation. 1994 Nov;90(5):2457-67 - PubMed
  38. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6753-7 - PubMed
  39. Cardiovasc Drugs Ther. 2009 Apr;23(2):129-35 - PubMed
  40. Am J Physiol. 1992 Dec;263(6 Pt 2):H857-65 - PubMed
  41. Circulation. 1999 May 11;99(18):2396-401 - PubMed
  42. Antioxid Redox Signal. 2009 Aug;11(8):1913-28 - PubMed
  43. PLoS One. 2012;7(3):e33438 - PubMed
  44. Am J Cardiol. 2013 May 15;111(10):1394-400 - PubMed
  45. Inflamm Res. 2013 Jul;62(7):637-40 - PubMed
  46. Circ Res. 2004 Jun 25;94(12):1543-53 - PubMed
  47. Circulation. 1994 Mar;89(3):1254-61 - PubMed
  48. Am J Cardiol. 2010 May 15;105(10):1371-1377.e1 - PubMed
  49. Free Radic Biol Med. 2010 May 1;48(9):1182-7 - PubMed
  50. Circ Res. 2017 May 12;120(10):1598-1613 - PubMed
  51. J Cardiovasc Pharmacol. 2014 Jul;64(1):1-6 - PubMed
  52. Cardiovasc Res. 2004 Aug 15;63(3):433-42 - PubMed
  53. Kidney Blood Press Res. 2011;34(1):20-33 - PubMed
  54. Am J Pathol. 1995 Feb;146(2):419-28 - PubMed
  55. Circulation. 2008 May 20;117(20):2670-83 - PubMed

Publication Types